TARCOCIMAB TEDROMER
UNII 7HW5CX6OD5
Substance Identification & Data
This profile provides standardized clinical and technical data for Tarcocimab Tedromer, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 7HW5CX6OD5.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2411896-53-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
7HW5CX6OD5
2411896-53-0
N/A
Detailed Substance Profile
Preferred Name
TARCOCIMAB TEDROMER
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
11774
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
KL-251
Identifier assigned by the United States Adopted Names Council.
Substance Type
Tarcocimab Tedromer
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Tarcocimab Tedromer. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Tarcocimab Tedromer
Common Names & Synonyms
Immunoglobulin G1 [240-alanine,241-alanine,243-alanine,449-cysteine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 g1-chain), disulfide with human-Mus musculus monoclonal OG1950 k-chain, (232®232'),(235®235')-bis(disulfide) with immunoglobulin G1 anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 g1-chain) disulfide with human-Mus musculus monoclonal OG1950 k-chain, 449-thioether with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6-diazahexadec-1-yl]-44-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-4,8,26,42-tetraoxo-2,13,16,19,22,29,32,35,38-nonaoxa-5,9,25,41-tetraazatetratetracont-1-yl]-2-[(2-bromo-2-methyl-1-oxopropoxy)methyl]-1,3-propanediyl]bis(2-bromo-2-methylpropanoate) core 9-arm star compd. With 4-hydroxy-N,N,N,10-tetramethyl-9-oxo-3,5,8-trioxa-4-phosphaundec-10-en-1-aminium inner salt 4-oxide homopolymer
Immunoglobulin G1-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody, conjugated via a linker to a nonaantennary dendrimer with phosphorylcholine polymer end groups; gamma1 heavy chain humanized (1-453) [VH (Homo sapiens IGHV3-30*02 (75.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v14 CH2 A1.3, A1.2 (CH1 R120>K (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A(240), L1.2>A (241), G1>A (243) (237-346), CH3 E12 (362), M14 (364), L123>C (449) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain humanized (1'-214') [VKAPPA (Homo sapiens IGKV1-16*01 (87.4%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV lacking the glutamine synthetase (GS-KO) gene, glycoform alfa, substituted at an average of one S atom of cysteine residues 449 and 449'' with the (3RS)-1-[1,1,1-tris({3-[2-(2,2,2-tris{[(2-{α-(bromo / ethoxy / hydro /hydroxy)poly[1-(10,10-dimethyl-6-oxido-6-oxo-2,5,7-trioxa-10-aza-6λ5-phosphaundecan-10-ium-1-oyl)-1-methylethane-1,2-diyl]-ω-yl}-2-methylpropanoyl)oxy]methyl}ethoxy)acetamido]propanamido}methyl)-16,32-dioxo-3,6,9,12,19,22,25,28-octaoxa-15,31- diazatetratriacontan-34-yl]-2,5-dioxopyrrolidin-1-yl (tedromer) group
TARCOCIMAB TEDROMER [USAN]
Tarcocimab tedromer [WHO-DD]
tarcocimab tedromer [INN]
Technical Codes
KSI-301
OG-1953
OG1953
